Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S. Kittai, Philip A. Thompson, Cecelia Miller et al.|Journal of Clinical Oncology|2024Cited by 43
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insightsNaveen Pemmaraju, Marina Konopleva, Nathaniel R. Wilson et al.|Leukemia Research|2022Cited by 18
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi Haddad, Tapan M. Kadia, Koji Sasaki et al.|JCO Oncology Practice|2024Cited by 11
ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic LeukemiaElias Jabbour, Hagop Kantarjian, Nicholas J. Short et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 7
Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular FeaturesWalid Macaron, Nicholas J. Short, Elias Jabbour et al.|Blood|2024Cited by 5